## World Academy of Science, Engineering and Technology International Journal of Biomedical and Biological Engineering Vol:11, No:07, 2017

## Pharmacogenetics Study of Dapsone-Induced Severe Cutaneous Adverse Reactions and HLA Class I Alleles in Thai Patients

**Authors:** Patompong Satapornpong, Therdpong Tempark, Pawinee Rerknimitr, Jettanong Klaewsongkram, Chonlaphat Sukasem

Abstract: Dapsone (4, 4'-diaminodiphenyl sulfone, DDS) is broadly used for the treatment of inflammatory diseases and infections such as; leprosy, Pneumocystis jiroveci pneumonia in patients with HIV infection, neutrophilic dermatoses, dermatitis herpetiformis and autoimmune bullous disease. The severe cutaneous adverse drug reactions (SCARs) including, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS) are rare but severe life-threatening adverse drug reactions. Dapsone is one of many culprit drugs induced SJS, TEN and DRESS. Notwithstanding, to our knowledge, there are no studies of the association of HLA class I alleles and dapsoneinduced SCARs in non-leprosy Thai patients. This investigation was a prospective cohort study, which performed in a total of 45 non-leprosy patients. Fifteen patients of dapsone-induced SCARs were classified as following the RegiSCAR criteria, and 30 dapsone-tolerant controls were exposed to dapsone more than 6 months without any evidence of cutaneous reactions. The genotyping of HLA-A, -B and -C were performed using sequence-specific oligonucleotides (PCR-SSOs). The Ethics Committee of Ramathibodi hospital, Mahidol University, approved this study. Among all HLA class I alleles, HLA-A\*24:07, HLA-B\*13:01, HLA-B\*15:02, HLA-C\*03:04 and HLA-C\*03:09 were significantly associated with dapsone-induced SCARs (OR = 10.55, 95% CI = 1.06 - 105.04, p = 0.0360; OR = 56.00, 95% CI = 8.27 - 379.22, p = 0.0001; OR = 7.00, 95% CI = 1.17 - 42.00, p = 0.0322; OR = 6.00, 95% CI = 1.24 - 29.07, p = 0.0425 and OR = 17.08, 95% CI = 0.82 - 355.45, p = 0.0321, respectively).Furthermore, HLA-B\*13:01 allele had strong association with dapsone-induced SJS-TEN and DRESS when compared with dapsone-tolerant controls (OR = 42.00, 95% CI = 2.88 - 612.31, p = 0.0064 and OR = 63.00, 95% CI = 7.72 - 513.94 and p = 0.0001, respectively). Consequently, HLA-B\*13:01 might serve as a pharmacogenetic marker for screening before initiating the therapy with dapsone for prevention of dapsone-induced SCARs.

Keywords: dapsone-induced SCARs, HLA-B\*13:01, HLA class I alleles, severe cutaneous adverse reactions, Thai

Conference Title: ICGP 2017: International Conference on Genomics and Pharmacogenomics

**Conference Location :** Paris, France **Conference Dates :** July 20-21, 2017